Lv1
48 积分 2025-01-06 加入
Combined agonism of nutrient receptors GPR40 and GPR119 with K‐757 and K‐833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus
14小时前
待确认
Safety, pharmacokinetics and pharmacodynamics of HRS ‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
1天前
已完结
World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults
24天前
已完结
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
2个月前
已完结
Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes
2个月前
已完结
Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis
2个月前
已完结
Prevalence and Treatment of Diabetes in China, 2013-2018
2个月前
已完结
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial
2个月前
已完结
The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis
2个月前
已完结
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
2个月前
已完结
皖公网安备34019202002308
